



We're constantly innovating to design
the diagnostic tests that will meet
tomorrow's health challenges.



PIONEERING DIAGNOSTICS

contents

1 page 04
Our Legacy

2 page 06
At a glance

3 page 08
Our Purpose

4 page 10
**Serving
Public Health**

5 page 16
Innovation

6 page 18
Planet

7 page 20
**Our Team
Members**

8 page 22
**Healthcare
Ecosystem**

9 page 24
**Extended
Company**

→ **A family-led company, bioMérieux has grown to become a world leader in *in vitro* diagnostics, paving the way to help make the world a healthier place.**

Improving patient health

Our solutions help clinicians to quickly and reliably identify infectious diseases, providing them with crucial information for optimal patient care.

Protecting consumer safety

Our expertise meets industrial microbiology needs, building innovative, precise technologies that ensure the quality and safety of food and pharmaceutical products.

“ *bioMérieux's entrepreneurial adventure is rooted in a strong family commitment to serve public health.*

True to our pioneering spirit, our ambition is to be the leading player in infectious disease diagnostics.

We remain focused on this goal as part of our long-term vision, bolstered by the commitment of our global teams and enabled by our science-based approach, with no borders between disciplines or geographies. ”

Alexandre Mérieux - Chairman of the Board of Directors

our legacy

4 generations
of a family
committed to
serving
public health



1897

Marcel Mérieux, student of Louis Pasteur,
founds Institut Mérieux



1937

Dr. Charles Mérieux
takes up the reins



1963

Alain Mérieux
creates bioMérieux



2023

Alexandre Mérieux is
bioMérieux Chairman
of the Board of Directors

Institut Mérieux

**Our family holding company shares its
experience in biology to improve medicine
and public health across the globe.**

To fight against **infectious diseases** and
cancers, Institut Mérieux imagines and
develops new approaches in the fields of
diagnostics, immunotherapy, food safety and
nutrition.



at a glance

16
R&D centers

€4 billion
in Sales in 2024

Directly present in
45
countries

18
bio-industrial
sites

14,600
team members
around the world

Serving
more than
160
countries
through a large
distribution network

Leader
in microbiology,
multiplexing
molecular biology
and blood culture



our purpose

→ We help make the world a healthier place.

Our dedication to public health is the thread that connects everything we do.

It connects us to our history - since 1963, we have been fulfilling the vision of the Mérieux family to **improve health**, while maintaining the values of **respect, accountability, transparency, and sharing**.

Building on our strong legacy, we understand that our expertise in infectious diseases and our international presence give us a **special duty to act as a responsible corporate citizen**, serving the **greater good** and the **community**.

This commitment also connects us with our environment - infectious diseases are one of the major threats to human kind. Their emergence and spread are dramatically accelerated by climate change and globalization. The risk of finding ourselves unarmed to face ultra-resistant bacteria is now a reality.


Diagnostics are a game changer in this fight. By pioneering diagnostic solutions, we help clinicians **improve patient care** and we help industries **prevent contamination** of the food and pharmaceuticals they produce.

At bioMérieux we are convinced that, only by taking into account our **entire ecosystem** and the **public interest**, will we be able to succeed in building a **healthier world** and a more **inclusive society**.

We pioneer, develop and produce high quality *in vitro* diagnostics to **improve public health worldwide**.




We sustain a robust business model that allows us to **invest in innovation and create value**.



We implement environmentally-responsible actions to **preserve the planet** as a healthy place to live.



We support the **inclusion, well-being and development** of our team members, who all help save lives.



We foster transparent and ethical **dialogue with the healthcare ecosystem** to advance diagnostics.



We build long-term partnerships to increase our **positive impact on local communities** and provide our **support to the most vulnerable populations**.



We are bioMérieux. We act for a positive impact. We act for a healthier world.

→ We pioneer, develop and produce **diagnostic solutions** (instruments, reagents, software and services) for healthcare professionals and industry players.

serving public health

MOLECULAR BIOLOGY

Molecular biology, including the syndromic approach, is based on the detection of the DNA or RNA genetic sequences that characterize a disease-causing agent in order to target several bacteria, viruses, yeast and parasites.

MICROBIOLOGY

Microbiology is based on culturing biological samples, identifying microorganisms and measuring their resistance to antibiotics.

IMMUNOASSAYS

Immunoassays use an immunological reaction to identify and quantify the presence of antigens and/or antibodies in a sample.

SYNDROMIC TESTING

Patients with an infectious disease generally present symptoms that are not specific enough to clinically identify what is making them ill.

The **strategy** to identify the disease-causing agents has traditionally been based on testing for the most likely cause of a disease, waiting for test results and, if they are negative, repeating the process.

The **syndromic approach** uses a single test for all the microorganisms suspected of causing an infectious disease, saving time and allowing the patient to begin appropriate treatment sooner.





our impact on major health challenges

Acute care

We provide solutions to diagnose acute non-infectious conditions, such as cardio-vascular or kidney diseases. Our large range of tests also support physicians in the timely identification and management of organ failures, like acute myocardial infarction, heart failure, pulmonary embolism and acute kidney injury.

Respiratory infections

Respiratory infections are both extremely common and potentially serious - they are responsible for 2.5* million deaths worldwide each year, a figure greatly aggravated since COVID-19.

Our diagnostic solutions help identify the infectious agent to allow the most appropriate treatment.

* 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Infectious diseases. 2018;18(11):1191-210.

Antimicrobial resistance

Our tests identify pathogens, detect their potential resistance to antibiotics, and analyze antibiotic susceptibility to help doctors determine precisely which treatment to prescribe. We help reduce the improper use of antibiotics and preserve their efficacy today and for future generations (Antimicrobial Stewardship).

Sepsis

Sepsis is a life-threatening condition following an infection against which the immune response is out of control. Every year, 49 million people* develop sepsis of whom 11 million do not survive. Beyond developing solutions that quickly recognize and diagnose the severity of an infection, we are committed to raising awareness of sepsis.

* source: Rudd KE et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211.

OUR ANTIMICROBIAL STEWARDSHIP (AMS) COMMITMENT

+30%

patient results¹
supporting AMS
by 2025 vs. 2019

≥80%

of referenced
antibiotics
addressed by
our Antibiotic
Susceptibility
Testing (AST)
solutions²

¹ 2019 estimation: 183 million results.

² At least 80% based on EUCAST List and 90% based on CLSI cat A, B, U Lists.



our impact on major health challenges



Food Quality & Safety

An estimated 600 million* people fall ill each year after eating contaminated food. We offer the most extensive range of manual and automated solutions for industrial microbiology to ensure food safety and quality. Our solutions are used to determine the quality of raw materials, perform controls of processes and the manufacturing environment, and test the quality of finished products.

* source: Havelaar AH et al. World Health Organization Global Estimates and Regional Comparisons of the Burden of Foodborne Disease in 2010. PLoS Med. 2015 Dec 3;12(12):e1001923.



Pharma Quality Control

At the heart of today's key players' strategies, smart Quality Control is a true public health requirement. Our suite of innovative solutions provides rapid, highly accurate methods to reduce risk, boost efficiency, facilitate regulatory compliance, and empower smarter, data driven decision-making - to ultimately provide critical therapies to patients quickly and safely.

→ True to our pioneering spirit, our R&D teams combine their knowledge of medical needs with new technologies to fight infectious diseases worldwide.

- Increasing the medical and predictive value of the results delivered by our diagnostic tests.
- Improving laboratory workflow and optimizing their overall operational performance.

Our innovation approach is based on:

- Internal innovation programs.
- Multidisciplinary, international public and private collaborations.
- Pivotal strategic acquisitions.
- Open innovation: sharing knowledge and competencies while promoting cooperation among businesses.

innovation

12.3%

of sales
reinvested
in R&D

473

patent families
in our portfolio

17

patents
applications
in 2024

3

joint research
laboratories

→ As a global Company, we have an important role to play in minimizing climate change and protecting our planet.

We take a 360° approach to environmental stewardship: our eco-friendly actions include reducing greenhouse gas emissions, water consumption and waste, developing eco-design, optimizing the lifecycle of our products, utilizing natural resources as efficiently as possible.



OUR COMMITMENT

- lowering our greenhouse gas emissions by **-50%***
- reduce our energy consumption by** **-50%**
- reduce our waste generation by** **-50%**
- reduce our water consumption by** **-45%**

Recognized by independent third parties

Our targets and approach have been approved by the Science Based Targets initiative as consistent with the levels required to meet the goals of the Paris Climate Agreement, and to keep global warming to 1.5°C, which, according to the latest climate science, is needed to prevent the most damaging effects of climate change.

* By 2030 in comparison with 2019, in absolute value.
** Per million euro turnover in 2025 compared to 2015.

Our members

→ We have always been visionaries, innovators, and pioneers, expanding the frontiers of knowledge in microbiology and saving lives.

/20/

Skills development

Professional training, talent management and in-house mobility and promotion remain our priorities. That's why we work to predict how skills needs will develop and ensure lifelong learning for employees.

Diversity & inclusion

We are convinced that the diversity of our teams fosters innovation along with competitive differentiation and supports our ability to achieve our public health mission.

/21/

OUR COMMITMENT in 2025

Safety at work:

Lost Day Incident Rate divided by

2* to 0.6

Diversity:

In corporate leadership team

>40%
of women

>35%
of international profiles
in Corporate Leadership team.

**versus 2021.*

Health & well-being

Whatever our roles and responsibilities, we adopt best practices to reduce the risks associated with the activities carried out at our sites and we are committed to reimagining the way we work to create a culture that inspires and empowers.

→ We strive to reduce non-compliance risks, generate learnings that can be applied to our organization and be recognized as a trusted partner in public health by all our stakeholders, with the sole interest of patients in mind.

healthcare ecosystem

- Nurturing exchanges with patients, consumers and Key Opinion Leaders on major health challenges related to infectious diseases.
- Raising awareness of medical and economic value of *in vitro* diagnostics for the lay public and public decision makers.
- Ensuring ethical business conduct and regulatory compliance.
- Guaranteeing responsible data management.

WE BELIEVE THAT CONNECTING WITH PATIENTS AND EXTERNAL SCIENTIFIC STAKEHOLDERS IS ESSENTIAL TO CREATE VALUE FOR BOTH OUR COMPANY AND SOCIETY.

- Collaborating with patient associations on educational programs.
- Involving patients in the definition of bioMérieux's innovation strategy and product development process.
- Highlighting the voice of patients through patient engagement and testimonials in our communications.

OUR COMMITMENT X2

COLLABORATION PROJECTS WITH PATIENT ASSOCIATIONS BY 2025

→ Taking responsibility in the countries where we are present and giving back to Society has always been an important part of our Company culture. That's why we support social and cultural initiatives happening around our sites and subsidiaries, especially those targeting the most vulnerable groups and young people, and encouraging our team members to volunteer, in partnership with local associations and NGOs.


OUR COMMITMENT

≥ 1%*

OF NET INCOME GROUP
SHARE DEDICATED TO
PHILANTHROPY

* Endowment Fund not included.

The **bioMérieux Endowment Fund for Education**, created in December 2020, is an independent legal structure endowed with 20 million euros by bioMérieux. Its mission is to promote equal opportunities in the countries where we operate, with the ambition of reducing inequalities through and within **education** so that everyone can find their place in the world.



Fondation
Mérieux

As part of the **Institut Mérieux group**, we dedicate a significant portion of our donations to support the actions of the **Mérieux Foundation**. This independent foundation with public interest status works in **low- and middle-income countries** to **combat infectious diseases, increase access to diagnostics and sustainably improve the health and quality of life of vulnerable populations**.

ALGERIA
 ARGENTINA
 AUSTRALIA
 AUSTRIA
 BELGIUM
 BRAZIL
 CANADA
 CHILE
 CHINA
 COLOMBIA
 CZECH REPUBLIC
 DENMARK
 EGYPT
 FINLAND
 FRANCE
 GERMANY
 GREECE
 HUNGARY
 INDIA
 ITALY
 IVORY COAST
 JAPAN
 KENYA
 KOREA
 MALAYSIA
 MEXICO
 NIGERIA
 NORWAY
 PHILIPPINES
 POLAND
 PORTUGAL
 RUSSIA
 SERBIA
 SINGAPORE
 SOUTH AFRICA
 SPAIN
 SWEDEN
 SWITZERLAND
 THAILAND
 THE NETHERLANDS
 TURKEY
 UNITED ARAB EMIRATES
 UNITED KINGDOM
 UNITED STATES
 VIETNAM